Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA794 | CA5076 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 78 |
| 2 | DDI | 43 |
| 3 | DDC | 13 |
| 4 | D4T | 30 |
| 5 | AZT+D4T | 18 |
| 6 | 3TC+AZT+IDV | 52 |
| 7 | D4T+DDI+NVP | 19 |
| 8 | 3TC+D4T+RTV+SQV | 58 |
| 9 | 3TC+DDI+EFV+RTV+SQV | 17 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, I54V, V82A, I84V, L90M | K43T | L10I, E35D, M36V, D60E, I62V, L63P, A71V |
| >CA5076| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEDVNLPGRWTPKLIGGIGGFVKVRQYE QVPIEICGHKVIGTVLVGPTPANVIGRNLMTQIGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, K65R, D67N, Q151M, L210W, T215Y | A62V, V75I, F116Y | L100I, K103KN, Y181I | V179D | M16V, K20R, V21I, V35I, K43Q, S68N, E79D, R83K, K122E, I167V, G196E, Q197K, D218E, K223Q, L228R, A272P, K277R |
| >CA5077| codons 1-302 PISPIETVPVKLKPGVDGPRIKQWPLTEEKIKALIEICTELEQEGKISKIGPENPYNTPV FVIKRKNNTKWRKLIDFRDLNKKTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYYSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKVLEPFRKQNPDIDI IQYMDDLYVGSDLEIEKHRTKIEELRQHLWRWGFYTPEKKHQQEPPFRWMGYELHPDKWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE LE |
References
| Author | Title | Citation |
| Palmer, S | Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. | AIDS, 1999 |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |